Hospital
Brim Holding Company, INC.
Brim Holding Company, INC. was paid $1.79M by Medicaid between Jan 2018 and Oct 2024, across 99 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 10% of everything it billed.
33Billing provider infoBRIM HOLDING COMPANY, INC.
HOPE, AR 71801
HOPE, AR 71801
33aNPI1922353754assigned 07/18/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.79M
24GClaims146,712
24DCodes billed99
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#29 of 49
Median peer was paid$2.62M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,261 | $164K | |
| 2019 | 26,156 | $237K | |
| 2020 | 20,427 | $191K | |
| 2021 | 23,020 | $269K | |
| 2022 | 22,962 | $366K | |
| 2023 | 19,274 | $309K | |
| 2024incomplete | 17,612 | $249K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 10% | 5,419 | 4,792 | $185K |
| 80053 | Comprehensive metabolic panel | 8.2% | 10,528 | 8,211 | $147K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.5% | 2,390 | 1,920 | $133K |
| 70450 | Computed tomography, head or brain; without contrast material | 6.3% | 1,563 | 1,301 | $113K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.0% | 2,418 | 2,030 | $107K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.2% | 9,201 | 4,126 | $93K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.8% | 6,031 | 1,105 | $85K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4.1% | 6,662 | 6,003 | $73K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.6% | 12,206 | 9,376 | $65K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 366 | 310 | $49K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 1,819 | 1,488 | $47K |
| 80050 | General health panel | 2.5% | 1,289 | 1,033 | $45K |
87 more codes
| 36415 | Collection of venous blood by venipuncture | 2.5% | 8,395 | $45K |
| 99284 | Emergency room visit (serious) | 2.2% | 1,633 | $39K |
| 71046 | Radiologic examination, chest; 2 views | 2.2% | 3,014 | $39K |
| 87081 | 1.9% | 4,089 | $33K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 3,726 | $30K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 235 | $28K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.5% | 533 | $27K |
| 87400 | 1.4% | 4,265 | $25K | |
| 84484 | 1.4% | 4,271 | $24K | |
| 80061 | Lipid panel | 1.3% | 2,840 | $24K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,140 | $18K |
| 82553 | <1% | 2,033 | $15K | |
| 81001 | <1% | 4,731 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,649 | $14K |
| 81025 | <1% | 1,698 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,940 | $13K |
| 86710 | <1% | 693 | $12K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 237 | $12K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 522 | $11K |
| 84703 | <1% | 1,152 | $10K | |
| 82550 | <1% | 2,160 | $10K | |
| 83735 | <1% | 2,256 | $9K | |
| 83880 | <1% | 761 | $9K | |
| 94760 | <1% | 900 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,447 | $9K |
| 87807 | <1% | 747 | $9K | |
| 81003 | <1% | 3,424 | $8K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 150 | $8K |
| 83690 | <1% | 1,404 | $8K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,586 | $7K |
| 87088 | <1% | 1,011 | $6K | |
| 80306 | <1% | 380 | $6K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 204 | $6K |
| 83605 | <1% | 903 | $6K | |
| 97161 | <1% | 433 | $6K | |
| 87186 | <1% | 1,193 | $5K | |
| 82150 | <1% | 871 | $5K | |
| 87040 | <1% | 637 | $5K | |
| 87420 | <1% | 399 | $5K | |
| 80320 | <1% | 286 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 148 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,446 | $4K |
| 74018 | <1% | 254 | $3K | |
| 87077 | <1% | 496 | $3K | |
| 80143 | <1% | 158 | $3K | |
| 80179 | <1% | 147 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 998 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 358 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 29 | $2K |
| 84436 | <1% | 775 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 86 | $2K |
| 97010 | <1% | 811 | $2K | |
| 71020 | <1% | 155 | $2K | |
| 73630 | <1% | 100 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 560 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 183 | $2K |
| 73030 | <1% | 77 | $2K | |
| 82077 | <1% | 98 | $1K | |
| 73610 | <1% | 115 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 54 | $1K |
| 85610 | <1% | 611 | $1K | |
| 84439 | <1% | 122 | $1K | |
| 85027 | <1% | 171 | $991.25 | |
| G0378 | Hospital observation service, per hour | <1% | 318 | $923.32 |
| 72100 | <1% | 56 | $895.34 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 282 | $778.05 |
| 85007 | <1% | 150 | $614.28 | |
| 80047 | <1% | 30 | $586.92 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12 | $559.06 |
| 82962 | <1% | 120 | $504.26 | |
| 85730 | <1% | 136 | $446.50 | |
| 73502 | <1% | 20 | $398.44 | |
| 80329 | <1% | 53 | $388.08 | |
| 73562 | <1% | 14 | $340.00 | |
| 83655 | <1% | 16 | $241.92 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 29 | $226.30 |
| 90715 | <1% | 13 | $115.20 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 303 | $114.00 |
| 71010 | <1% | 14 | $108.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14 | $86.25 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 32 | $54.29 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,287 | $14.60 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 15 | $8.91 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 29 | $5.17 |
| A9270 | Non-covered item or service | <1% | 3,951 | $0.10 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 14 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGILBERT, THOMAS (HOSPITAL CEO)
| Provider | Location | Paid |
|---|---|---|
| Brim Healthcare of Texas LLC | Texarkana, TX | $6.26M |
| Brim Holding Company, INC. | Hope, AR | $222K |
| Brim Holding Company, INC. | Hope, AR | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.